iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
iBio highlighted preclinical data showing IBIO-610, a potential first-in-class Activin E antibody, preserved lean mass in obese non-human primates when combined with semaglutide. In the eight-week NHP study (n=6 per group), only 6% of weight lost with the combination was lean mass versus 22% with semaglutide alone; fat made up 93% of weight lost with the combination versus 77% with semaglutide alone. IBIO-610 also showed a 97% reduction in active serum Activin E and a 33.2-day NHP half-life, with a projected human half-life supporting twice-yearly dosing.
Key figures
- Drug Name
- IBIO-610
- Phase Of Trial
- preclinical (non-human primate)
- Study weeks
- 8
- Nhp half life days
- 33.2
- Activin e reduction week8
- 97%
- Fat share of weight loss combo
- 93%
- Lean mass share of weight loss combo
- 6%
- Fat share of weight loss semaglutide alone
- 77%
- Lean mass share of weight loss semaglutide alone
- 22%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.